|
|
|
1-10 employees
View all
|
|
Pharmaceuticals
|
|
850 N 5th Street, Phoenix, AZ 85004, US
|
|
OncoMyx Therapeutics targets hematologic and solid tumors with unique oncolytic virus called myxoma (MYXV) and a novel patented systemic delivery approach. The myxoma program is the result of two decades of oncolytic virus research in the laboratory of Professor Grant McFadden. Myxoma is a pox virus that is highly immunostimulatory, and is non-pathogenic in any organism outside of rabbits. The virus has a unique ability to be carried systemically by human leukocytes where it can then infect tumor cells. Programs are in development for both hematology (myeloma and AML) as well as solid tumors. Professor McFadden sequenced the myxoma virus genome in 1999, and since then has produced dozens of genetically engineered constructs, demonstrating its ability as an oncolytic agent across many tumors in preclinical cell and animal models.
|
OncoMyx Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used OncoMyx Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact OncoMyx Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.